The COPD Foundation, a 501(c)(3) nonprofit organization, has a mission to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. We do this by expanding services, accelerating innovations for more effective and affordable treatments, and promoting awareness and education, with the overarching goal of preventing chronic lung disease, slowing its progression, and ultimately finding a cure.
Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. | Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.
Chiesi USA
Chiesi is a global biopharmaceutical company that develops and markets innovative therapeutic solutions in respiratory health, rare diseases and specialty care. Through its US affiliate headquartered in Cary, NC, the company is bringing a fresh perspective to the US respiratory landscape that is informed by 90 years of global pharmaceutical leadership. As a privately-owned, values-driven pharmaceutical company that is committed to generating economic value in a way that benefits society, Chiesi seeks to create lasting, shared value for people, patients, the planet, and our business.
Canadian Thoracic Society
The Canadian Thoracic Society (CTS) is Canada’s national inter-professional specialty society for respirology bringing together over 1,000 members representing specialists, physicians, researchers and healthcare professionals from a variety of disciplines working in respiratory health. For more information on CTS, please visit our website at www.cts-sct.ca
Bronchiectasis and NTM Association
The mission of the Bronchiectasis and NTM Association is to improve the lives of people with bronchiectasis, NTM lung disease, or both conditions. We accomplish this by providing education, supporting advocacy, furthering research, and advancing high-quality, specialized care. Our organization offers a variety of programs including an online social community, a comprehensive website with robust educational materials and resources, a global disease awareness campaign, a longitudinal patient registry, and a large network of centers collaborating to improve patient care. We collaborate with a variety stakeholders, including patients, caregivers, health care providers, industry companies, and government entities, understanding the importance that each stakeholder group plays in working towards our mission. Our medical and scientific leadership includes Dr. Doreen Addrizzo-Harris, who oversees the Bronchiectasis and NTM Care Center Network, Dr. Timothy Aksamit, who oversees our educational resource development and World Bronchiectasis Day campaign, and Dr. Charles Daley, who oversees our research programs.
Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. Baxter employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Hillrom products are now part of Baxter’s global portfolio. | Baxter International Inc. through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. | Baxter products and therapies can be found throughout hospitals and clinics – from the ER to the OR, from the pharmacy to the ICU – as well as advancing patients’ care in their homes. For 90 years, we have been at the critical intersection of saving and sustaining lives. We have pioneered significant medical innovations that changed healthcare. From the first commercially produced intravenous solutions to today’s leading acute, nutritional, renal and surgical care innovations, we are committed to providing leading healthcare solutions.
Asian Pacific Society of Respirology
The objectives of the APSR are the advancement and promotion of knowledge of the respiratory system in health and disease. The Society strives to encourage research, improve clinical practice through training, increase awareness of health problems and promote the exchange of knowledge among respirologists in the Asia-Pacific region and beyond.